Skip to main content

Publications

Key publications-Faculty

De Veirman, K., Menu, E., Maes, K., De Beule, N., De Smedt, E., Maes, A., ... Van Valckenborgh, E. (2019). Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters, 442, 233-241. https://doi.org/10.1016/j.canlet.2018.11.002

Maes, A., Maes, K., De Raeve, H., De Smedt, E., Vlummens, P., Szablewski, V., ... De Bruyne, E. (2019). The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. British Journal of Cancer, 120(12), 1137-1146. https://doi.org/10.1038/s41416-019-0471-0

De Beck, L., Melhaoui, S., De Veirman, K., Menu, E., De Bruyne, E., Vanderkerken, K., ... Maes, K. (2018). Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects. OncoImmunology, 7(10), [e1484981]. https://doi.org/10.1080/2162402X.2018.1484981

Faict, S., Muller, J., De Veirman, K., De Bruyne, E., Maes, K., Vrancken, L., ... Menu, E. (2018). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal, 8(11), 105-105. [105]. https://doi.org/10.1038/s41408-018-0139-7

De Smedt, E., Maes, K., Verhulst, S., Liu, H., Kassambara, A., Maes, A., ... De Bruyne, E. (2018). Loss of RASSF4 expression in multiple myeloma promotes RAS-driven malignant progression. Cancer Research, 78(5), 1155-1168. https://doi.org/10.1158/0008-5472.CAN-17-1544

Maes, K., Boeckx, B., Vlummens, P., De Veirman, K., Menu, E., Vanderkerken, K., ... De Bruyne, E. (2018). The genetic landscape of 5T models for multiple myeloma. Scientific Reports, 8(1), [15030]. https://doi.org/10.1038/s41598-018-33396-w

De Veirman, K., De Beule, N., Maes, K., Menu, E., De Bruyne, E., De Raeve, H., ... Van Valckenborgh, E. (2017). Extracellular S100A9 protein in bone marrow supports multiple myeloma survival by stimulating angiogenesis and cytokine secretion. Cancer Immunology Research, 5(10), 839-846. https://doi.org/10.1158/2326-6066.CIR-17-0192

Favreau, M., Menu, E., Gaublomme, D., Vanderkerken, K., Faict, S., Maes, K., ... Elewaut, D. (2017). Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma. Leukemia, 31(12), 2678-2685. https://doi.org/10.1038/leu.2017.146

Frassanito, M., De Veirman, K., Desantis, V., Marzo, L. D., Vergara, D., Ruggieri, S., ... Vacca, A. (2016). Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia, 30(3), 640-648. https://doi.org/10.1038/leu.2015.289

Wang, J., Hendrix, A., Hernot, S., Lemaire, M., De Bruyne, E., Van Valckenborgh, E., ... Menu, E. (2014). Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood, 124(4), 555-566.

Maes, K., De Smedt, E., Lemaire, M., De Raeve, H., Menu, E., Van Valckenborgh, E., ... De Bruyne, E. (2014). The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget, 5(10), 3115-3129.

De Bruyne, E., Bos, T., Schuit, F., Van Valckenborgh, E., Menu, E., Thorrez, L., ... Vanderkerken, K. (2010). IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood, 115(12), 2430-2440.